Selective Serotonin Reuptake Inhibitors and Risk of Serotonin Syndrome as Consequence of Drug-Drug Interactions: Analysis of the FDA Adverse Event Reporting System
Medical Principles and Practice · 2025
DOI: 10.1159/000546109 ↗Kurz gefasst
Fachartikel in der Zeitschrift Medical Principles and Practice, 2025. Verfasst von Chiara Elli und 3 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Clinical Pharmacology and Appropriateness of Drug Prescription, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy. Hauptthemen laut MEDLINE: Serotonin Syndrome, Selective Serotonin Reuptake Inhibitors, Adverse Drug Reaction Reporting Systems. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Medications exhibiting serotonergic properties, such as selective serotonin reuptake inhibitors (SSRIs) antidepressants, opioids, and other antidepressants can induce serotonin syndrome, a rare but potentially life-threatening adverse event.
Aim
This study aims to investigate the risks of serotonin syndrome among different SSRIs and assess the influence of drug-drug interactions with other medications.
Methods
We analyzed the suspected adverse events in the US Food and Drug Administration Adverse Event Reporting System (FAERS) database.
Results
We identified 13,312 reports of serotonin syndrome, 52% of which involved SSRIs (n = 6,921), with reporting odds ratios (RORs) of 24.19. Among the safety reports involving SSRIs, 4,851 cases reported at least one severe outcome. All active substances of the SSRI group were associated with serotonin syndrome, sertraline, and fluoxetine had the most reports, while fluvoxamine had the highest ROR and risk compared to all other SSRIs (ROR: 2.66, 95% confidence interval: 2.33–3.05). The combinations of SSRIs with other drugs with the most reported cases were SSRIs-antidepressants (n = 2,395) and SSRIs-opioids (n = 2,252). The combinations of SSRIs with serotonin-norepinephrine reuptake inhibitors (ROR 25.42) and “other antidepressants” (ROR 22.74) were associated with a signal for serotonin syndrome. The combination SSRIs-opioids was associated with a safety signal, particularly those with higher risk for serotonin syndrome, like tramadol and fentanyl (ROR 41.95).
Conclusion
Close monitoring for symptoms of serotonin syndrome should be considered in patients with depression with a combination of antidepressants, and in those on SSRIs who also require linezolid, monoamine oxidase inhibitors or high-risk opioids, like tramadol, or fentanyl.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Clinical Pharmacology and Appropriateness of Drug Prescription, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.
Zitieren
APA
Elli, C., Novella, A., Elli, C., & Pasina, L. (2025). Selective Serotonin Reuptake Inhibitors and Risk of Serotonin Syndrome as Consequence of Drug-Drug Interactions: Analysis of the FDA Adverse Event Reporting System. Medical Principles and Practice. https://doi.org/10.1159/000546109
Vancouver
Elli C, Novella A, Elli C, Pasina L. Selective Serotonin Reuptake Inhibitors and Risk of Serotonin Syndrome as Consequence of Drug-Drug Interactions: Analysis of the FDA Adverse Event Reporting System. Medical Principles and Practice. 2025. doi:10.1159/000546109
BibTeX
@article{Elli2025,
author = {Elli, Chiara and Novella, Alessio and Elli, Chiara and Pasina, Luca},
title = {Selective Serotonin Reuptake Inhibitors and Risk of Serotonin Syndrome as Consequence of Drug-Drug Interactions: Analysis of the FDA Adverse Event Reporting System},
journal = {Medical Principles and Practice},
year = {2025},
doi = {10.1159/000546109}
}
EUVIMED